Literature DB >> 17400327

Are chromosomal imbalances important in cancer?

Raymond L Stallings1.   

Abstract

Tumor-specific patterns of large-scale chromosomal imbalances characterize most forms of cancer. Based on evidence primarily from neuroblastomas, it can be argued that large-scale chromosomal imbalances are crucial for tumor pathogenesis and have an impact on the global transcriptional profile of cancer cells, and that some imbalances even initiate cancer. The genes and genetic pathways that have been dysregulated by such imbalances remain surprisingly elusive. Many genes are affected by the regions of gain and loss, and there are complex interactions and relationships that occur between these genes, hindering their identification. The study of untranslated RNA sequences, such as microRNAs, is in its infancy, and it is likely that such sequences are also dysregulated by chromosomal imbalance, contributing to pathogenesis.

Entities:  

Mesh:

Year:  2007        PMID: 17400327     DOI: 10.1016/j.tig.2007.03.009

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  12 in total

1.  MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.

Authors:  Jennifer Lynch; Joanna Fay; Maria Meehan; Kenneth Bryan; Karen M Watters; Derek M Murphy; Raymond L Stallings
Journal:  Carcinogenesis       Date:  2012-03-01       Impact factor: 4.944

2.  Paraganglioma of the urinary bladder with chromosome duplications detected by fluorescence in situ hybridization in urine exfoliated cells: A case report.

Authors:  Chunguang Yang; Zheng Liu; Ruzhu Lan; Zhihua Wang; Zhiquan Hu; Zhiqiang Chen; Zhangqun Ye
Journal:  Oncol Lett       Date:  2015-11-18       Impact factor: 2.967

Review 3.  MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation.

Authors:  Raymond L Stallings; Niamh H Foley; Isabella M Bray; Sudipto Das; Patrick G Buckley
Journal:  Semin Cancer Biol       Date:  2011-07-13       Impact factor: 15.707

Review 4.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

5.  Target chromosomes of inducible deletion by a Cre/inverted loxP system in mouse embryonic stem cells.

Authors:  Masako Tada; Hiroyuki Matsumura; Yuko Kurose; Norio Nakatsuji; Takashi Tada
Journal:  Chromosome Res       Date:  2009-03-31       Impact factor: 5.239

Review 6.  MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics.

Authors:  R L Stallings
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma.

Authors:  Amanda Tivnan; Lorraine Tracey; Patrick G Buckley; Leah C Alcock; Andrew M Davidoff; Raymond L Stallings
Journal:  BMC Cancer       Date:  2011-01-25       Impact factor: 4.430

8.  miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.

Authors:  Marta Terrile; Kenneth Bryan; Lynsey Vaughan; Albert Hallsworth; Hannah Webber; Louis Chesler; Raymond L Stallings
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

9.  arrayMap: a reference resource for genomic copy number imbalances in human malignancies.

Authors:  Haoyang Cai; Nitin Kumar; Michael Baudis
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

10.  Chromosomal bands affected by acute oil exposure and DNA repair errors.

Authors:  Gemma Monyarch; Fernanda de Castro Reis; Jan-Paul Zock; Jesús Giraldo; Francisco Pozo-Rodríguez; Ana Espinosa; Gema Rodríguez-Trigo; Hector Verea; Gemma Castaño-Vinyals; Federico P Gómez; Josep M Antó; Maria Dolors Coll; Joan Albert Barberà; Carme Fuster
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.